The delay in Dr. Reddy's gCopaxone will benefit Natco as it launched the drug in October 2017 and has only one generic competitor in this product category. Natco Pharma gained 5% in the opening hour trades today on the back of news that Dr. Reddy’s gCopaxone will get delayed further (read Dr. Reddy's Q4 result and concall notes). This leaves the gCopaxone competition limited to only two players i.e. Sandoz and Natco’s partner Mylan.
To Get Free Trial
Missed call @ 9582541010
Call Us @ 8822117117
Mail Us = starindiamarket@gmail.com
Visit = http://www.starindiaresearch.com/freetrail.php
To Get Free Trial
Missed call @ 9582541010
Call Us @ 8822117117
Mail Us = starindiamarket@gmail.com
Visit = http://www.starindiaresearch.com/freetrail.php
No comments:
Post a Comment